GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ligand Pharmaceuticals Inc (NAS:LGND) » Definitions » Days Payable

Ligand Pharmaceuticals (Ligand Pharmaceuticals) Days Payable : 136.29 (As of Dec. 2023)


View and export this data going back to 1995. Start your Free Trial

What is Ligand Pharmaceuticals Days Payable?

Ligand Pharmaceuticals's average Accounts Payable for the three months ended in Dec. 2023 was $2.5 Mil. Ligand Pharmaceuticals's Cost of Goods Sold for the three months ended in Dec. 2023 was $1.6 Mil. Hence, Ligand Pharmaceuticals's Days Payable for the three months ended in Dec. 2023 was 136.29.

The historical rank and industry rank for Ligand Pharmaceuticals's Days Payable or its related term are showing as below:

LGND' s Days Payable Range Over the Past 10 Years
Min: 35.77   Med: 152.04   Max: 370.25
Current: 180.04

During the past 13 years, Ligand Pharmaceuticals's highest Days Payable was 370.25. The lowest was 35.77. And the median was 152.04.

LGND's Days Payable is ranked better than
55.1% of 715 companies
in the Biotechnology industry
Industry Median: 148.78 vs LGND: 180.04

Ligand Pharmaceuticals's Days Payable increased from Dec. 2022 (44.74) to Dec. 2023 (136.29). It may suggest that Ligand Pharmaceuticals delayed paying its suppliers.


Ligand Pharmaceuticals Days Payable Historical Data

The historical data trend for Ligand Pharmaceuticals's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ligand Pharmaceuticals Days Payable Chart

Ligand Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Days Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 106.20 37.22 35.77 47.36 134.27

Ligand Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Days Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 44.74 140.45 429.65 157.85 136.29

Competitive Comparison of Ligand Pharmaceuticals's Days Payable

For the Biotechnology subindustry, Ligand Pharmaceuticals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ligand Pharmaceuticals's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ligand Pharmaceuticals's Days Payable distribution charts can be found below:

* The bar in red indicates where Ligand Pharmaceuticals's Days Payable falls into.



Ligand Pharmaceuticals Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Ligand Pharmaceuticals's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

Days Payable (A: Dec. 2023 )
=Average Accounts Payable /Cost of Goods Sold*Days in Period
=( (Accounts Payable (A: Dec. 2022 ) + Accounts Payable (A: Dec. 2023 )) / count ) / Cost of Goods Sold (A: Dec. 2023 )*Days in Period
=( (5.307 + 2.427) / 2 ) / 10.512*365
=3.867 / 10.512*365
=134.27

Ligand Pharmaceuticals's Days Payable for the quarter that ended in Dec. 2023 is calculated as:

Days Payable (Q: Dec. 2023 )
=Average Accounts Payable / Cost of Goods Sold*Days in Period
=( (Accounts Payable (Q: Sep. 2023 ) + Accounts Payable (Q: Dec. 2023 )) / count ) / Cost of Goods Sold (Q: Dec. 2023 )*Days in Period
=( (2.475 + 2.427) / 2 ) / 1.641*365 / 4
=2.451 / 1.641*365 / 4
=136.29

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ligand Pharmaceuticals Days Payable Related Terms

Thank you for viewing the detailed overview of Ligand Pharmaceuticals's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.


Ligand Pharmaceuticals (Ligand Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
3911 Sorrento Valley Boulevard, Suite 110, San Diego, CA, USA, 92121
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
Executives
Martine Zimmermann director C/O LIGAND PHARMACEUTICALS INCORPORATED, 3911 SORRENTO VALLEY BOULEVARD SUITE 110, SAN DIEGO CA 92121
Todd C Davis director 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Andrew Reardon officer: CHIEF LEGAL OFFICER & C/O LIGAND PHARMACEUTICALS INCORPORATED, 3911 SORRENTO VALLEY BLVD, SUITE 110, SAN DIEGO CA 92121
Octavio Espinoza officer: Chief Financial Officer C/O LIGAND PHARMACEUTICALS INC, 3911 SORRENTO VALLEY BOULEVARD, STE 110, SAN DIEGO CA 92121
John W Kozarich director 10275 SCIENCE CENTER DR, SAN DIEGO CA 92121
Stephen L Sabba director DORSET MANAGEMENT CORP, 485 UNDERHILL BLVD SUITE 205, SYOSSET NY 11791
John L Higgins officer: CEO & President 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Jason Haas director C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Matthew W Foehr officer: EVP and COO 11119 NORTH TORREY PINES RD #200, LA JOLLA CA 92037
John L Lamattina director 81 WYMAN ST, POST OFFICE BOX 9046, WALTHAM MA 02454
Jennifer R. Cochran director C/O LIGAND PHARMACEUTICALS INC, 3911 SORRENTO VALLEY BOULEVARD, STE 100, SAN DIEGO CA 92121
Charles S Berkman officer: Asso. Gen. Counsel, Secretary 11085 NORTH TORREY PINES ROAD, SUITE 300, LA JOLLA CA 92037
Sunil Patel director 11085 NORTH TORREY PINES RD., SUITE 300, LA JOLLA CA 92037
Goldman Sachs Group Inc 10 percent owner 200 WEST STREET, NEW YORK NY 10282
Goldman Sachs & Co. Llc 10 percent owner 200 WEST STREET, NEW YORK NY 10282